Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone
- 30 April 2003
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 30 (2) , 265-269
- https://doi.org/10.1053/sonc.2003.50079
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Treatment of Waldenström’s Macroglobulinemia With RituximabJournal of Clinical Oncology, 2002
- Treatment of Waldenstrom’s Macroglobulinemia With ThalidomideJournal of Clinical Oncology, 2001
- Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)Blood, 2001
- Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucilBritish Journal of Haematology, 2000
- Waldenström’s Macroglobulinemia: Clinical Features, Complications, and ManagementJournal of Clinical Oncology, 2000
- World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997Journal of Clinical Oncology, 1999
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.Journal of Clinical Oncology, 1994
- Waldenstrom's macroglobulinemiaBlood, 1994
- The Spectrum of IgM Monoclonal Gammopathy in 430 CasesMayo Clinic Proceedings, 1987